The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Metformin-Pioglitazone Market Research Report 2025
Synopsis
Metformin/pioglitazone is used to lower blood sugar levels in type 2 diabetes. It’s used along with diet and exercise.
The global Metformin-Pioglitazone market was valued at US$ 141 million in 2023 and is anticipated to reach US$ 179.1 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
The combination of metformin and pioglitazone is commonly used in the treatment of type 2 diabetes mellitus. This combination medication works in different ways to help control blood sugar levels and improve insulin sensitivity. Metformin and pioglitazone have both demonstrated efficacy in managing diabetes. Combining these two medications can provide better glycemic control compared to using either drug alone. The dual mechanism of action helps address the underlying causes of insulin resistance and impaired glucose metabolism, leading to improved outcomes for patients. Metformin and pioglitazone have complementary actions. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while pioglitazone increases peripheral glucose utilization and reduces insulin resistance. This combination maximizes the benefits of each drug and offers a more comprehensive approach to diabetes treatment. The safety profiles of metformin and pioglitazone are well established. Metformin is generally well-tolerated, and pioglitazone has a well-documented safety record. By combining these drugs, physicians can minimize the risk of adverse effects associated with higher doses of a single medication. Diabetes is a complex and chronic condition that often requires a multifaceted treatment approach. The metformin-pioglitazone combination provides comprehensive glycemic control by targeting multiple pathways involved in glucose regulation. This makes it an attractive option for healthcare providers seeking an effective and convenient treatment strategy. With the rising prevalence of type 2 diabetes globally, there is an increasing demand for effective and well-tolerated treatment options. Metformin-pioglitazone combination therapy has gained market acceptance due to its proven efficacy, safety, and convenience.
This report aims to provide a comprehensive presentation of the global market for Metformin-Pioglitazone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metformin-Pioglitazone.
Report Scope
The Metformin-Pioglitazone market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metformin-Pioglitazone market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metformin-Pioglitazone companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda Pharmaceuticals
Mylan
Teva
Sandoz
Aurobindo Pharma
MACLEODS
Torrent Pharmaceuticals
Wellona Pharma
BLUE CROSS
Neurocon Inc
Segment by Type
Tablets: 15 mg pioglitazone/1000 mg metformin HCl
Tablets: 30 mg pioglitazone/1000 mg metformin HCl
Segment by Application
Hospital
Drug store
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metformin-Pioglitazone companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Metformin/pioglitazone is used to lower blood sugar levels in type 2 diabetes. It’s used along with diet and exercise.
The global Metformin-Pioglitazone market was valued at US$ 141 million in 2023 and is anticipated to reach US$ 179.1 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
The combination of metformin and pioglitazone is commonly used in the treatment of type 2 diabetes mellitus. This combination medication works in different ways to help control blood sugar levels and improve insulin sensitivity. Metformin and pioglitazone have both demonstrated efficacy in managing diabetes. Combining these two medications can provide better glycemic control compared to using either drug alone. The dual mechanism of action helps address the underlying causes of insulin resistance and impaired glucose metabolism, leading to improved outcomes for patients. Metformin and pioglitazone have complementary actions. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while pioglitazone increases peripheral glucose utilization and reduces insulin resistance. This combination maximizes the benefits of each drug and offers a more comprehensive approach to diabetes treatment. The safety profiles of metformin and pioglitazone are well established. Metformin is generally well-tolerated, and pioglitazone has a well-documented safety record. By combining these drugs, physicians can minimize the risk of adverse effects associated with higher doses of a single medication. Diabetes is a complex and chronic condition that often requires a multifaceted treatment approach. The metformin-pioglitazone combination provides comprehensive glycemic control by targeting multiple pathways involved in glucose regulation. This makes it an attractive option for healthcare providers seeking an effective and convenient treatment strategy. With the rising prevalence of type 2 diabetes globally, there is an increasing demand for effective and well-tolerated treatment options. Metformin-pioglitazone combination therapy has gained market acceptance due to its proven efficacy, safety, and convenience.
This report aims to provide a comprehensive presentation of the global market for Metformin-Pioglitazone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metformin-Pioglitazone.
Report Scope
The Metformin-Pioglitazone market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metformin-Pioglitazone market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metformin-Pioglitazone companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda Pharmaceuticals
Mylan
Teva
Sandoz
Aurobindo Pharma
MACLEODS
Torrent Pharmaceuticals
Wellona Pharma
BLUE CROSS
Neurocon Inc
Segment by Type
Tablets: 15 mg pioglitazone/1000 mg metformin HCl
Tablets: 30 mg pioglitazone/1000 mg metformin HCl
Segment by Application
Hospital
Drug store
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metformin-Pioglitazone companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metformin-Pioglitazone Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablets: 15 mg pioglitazone/1000 mg metformin HCl
1.2.3 Tablets: 30 mg pioglitazone/1000 mg metformin HCl
1.3 Market by Application
1.3.1 Global Metformin-Pioglitazone Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drug store
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metformin-Pioglitazone Market Perspective (2019-2030)
2.2 Metformin-Pioglitazone Growth Trends by Region
2.2.1 Global Metformin-Pioglitazone Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metformin-Pioglitazone Historic Market Size by Region (2019-2024)
2.2.3 Metformin-Pioglitazone Forecasted Market Size by Region (2025-2030)
2.3 Metformin-Pioglitazone Market Dynamics
2.3.1 Metformin-Pioglitazone Industry Trends
2.3.2 Metformin-Pioglitazone Market Drivers
2.3.3 Metformin-Pioglitazone Market Challenges
2.3.4 Metformin-Pioglitazone Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metformin-Pioglitazone Players by Revenue
3.1.1 Global Top Metformin-Pioglitazone Players by Revenue (2019-2024)
3.1.2 Global Metformin-Pioglitazone Revenue Market Share by Players (2019-2024)
3.2 Global Metformin-Pioglitazone Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metformin-Pioglitazone Revenue
3.4 Global Metformin-Pioglitazone Market Concentration Ratio
3.4.1 Global Metformin-Pioglitazone Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metformin-Pioglitazone Revenue in 2023
3.5 Metformin-Pioglitazone Key Players Head office and Area Served
3.6 Key Players Metformin-Pioglitazone Product Solution and Service
3.7 Date of Enter into Metformin-Pioglitazone Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metformin-Pioglitazone Breakdown Data by Type
4.1 Global Metformin-Pioglitazone Historic Market Size by Type (2019-2024)
4.2 Global Metformin-Pioglitazone Forecasted Market Size by Type (2025-2030)
5 Metformin-Pioglitazone Breakdown Data by Application
5.1 Global Metformin-Pioglitazone Historic Market Size by Application (2019-2024)
5.2 Global Metformin-Pioglitazone Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Metformin-Pioglitazone Market Size (2019-2030)
6.2 North America Metformin-Pioglitazone Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Metformin-Pioglitazone Market Size by Country (2019-2024)
6.4 North America Metformin-Pioglitazone Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metformin-Pioglitazone Market Size (2019-2030)
7.2 Europe Metformin-Pioglitazone Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Metformin-Pioglitazone Market Size by Country (2019-2024)
7.4 Europe Metformin-Pioglitazone Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metformin-Pioglitazone Market Size (2019-2030)
8.2 Asia-Pacific Metformin-Pioglitazone Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Metformin-Pioglitazone Market Size by Region (2019-2024)
8.4 Asia-Pacific Metformin-Pioglitazone Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metformin-Pioglitazone Market Size (2019-2030)
9.2 Latin America Metformin-Pioglitazone Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Metformin-Pioglitazone Market Size by Country (2019-2024)
9.4 Latin America Metformin-Pioglitazone Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metformin-Pioglitazone Market Size (2019-2030)
10.2 Middle East & Africa Metformin-Pioglitazone Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Metformin-Pioglitazone Market Size by Country (2019-2024)
10.4 Middle East & Africa Metformin-Pioglitazone Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Company Detail
11.1.2 Takeda Pharmaceuticals Business Overview
11.1.3 Takeda Pharmaceuticals Metformin-Pioglitazone Introduction
11.1.4 Takeda Pharmaceuticals Revenue in Metformin-Pioglitazone Business (2019-2024)
11.1.5 Takeda Pharmaceuticals Recent Development
11.2 Mylan
11.2.1 Mylan Company Detail
11.2.2 Mylan Business Overview
11.2.3 Mylan Metformin-Pioglitazone Introduction
11.2.4 Mylan Revenue in Metformin-Pioglitazone Business (2019-2024)
11.2.5 Mylan Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Metformin-Pioglitazone Introduction
11.3.4 Teva Revenue in Metformin-Pioglitazone Business (2019-2024)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Detail
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Metformin-Pioglitazone Introduction
11.4.4 Sandoz Revenue in Metformin-Pioglitazone Business (2019-2024)
11.4.5 Sandoz Recent Development
11.5 Aurobindo Pharma
11.5.1 Aurobindo Pharma Company Detail
11.5.2 Aurobindo Pharma Business Overview
11.5.3 Aurobindo Pharma Metformin-Pioglitazone Introduction
11.5.4 Aurobindo Pharma Revenue in Metformin-Pioglitazone Business (2019-2024)
11.5.5 Aurobindo Pharma Recent Development
11.6 MACLEODS
11.6.1 MACLEODS Company Detail
11.6.2 MACLEODS Business Overview
11.6.3 MACLEODS Metformin-Pioglitazone Introduction
11.6.4 MACLEODS Revenue in Metformin-Pioglitazone Business (2019-2024)
11.6.5 MACLEODS Recent Development
11.7 Torrent Pharmaceuticals
11.7.1 Torrent Pharmaceuticals Company Detail
11.7.2 Torrent Pharmaceuticals Business Overview
11.7.3 Torrent Pharmaceuticals Metformin-Pioglitazone Introduction
11.7.4 Torrent Pharmaceuticals Revenue in Metformin-Pioglitazone Business (2019-2024)
11.7.5 Torrent Pharmaceuticals Recent Development
11.8 Wellona Pharma
11.8.1 Wellona Pharma Company Detail
11.8.2 Wellona Pharma Business Overview
11.8.3 Wellona Pharma Metformin-Pioglitazone Introduction
11.8.4 Wellona Pharma Revenue in Metformin-Pioglitazone Business (2019-2024)
11.8.5 Wellona Pharma Recent Development
11.9 BLUE CROSS
11.9.1 BLUE CROSS Company Detail
11.9.2 BLUE CROSS Business Overview
11.9.3 BLUE CROSS Metformin-Pioglitazone Introduction
11.9.4 BLUE CROSS Revenue in Metformin-Pioglitazone Business (2019-2024)
11.9.5 BLUE CROSS Recent Development
11.10 Neurocon Inc
11.10.1 Neurocon Inc Company Detail
11.10.2 Neurocon Inc Business Overview
11.10.3 Neurocon Inc Metformin-Pioglitazone Introduction
11.10.4 Neurocon Inc Revenue in Metformin-Pioglitazone Business (2019-2024)
11.10.5 Neurocon Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Metformin-Pioglitazone Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tablets: 15 mg pioglitazone/1000 mg metformin HCl
Table 3. Key Players of Tablets: 30 mg pioglitazone/1000 mg metformin HCl
Table 4. Global Metformin-Pioglitazone Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Metformin-Pioglitazone Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Metformin-Pioglitazone Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Metformin-Pioglitazone Market Share by Region (2019-2024)
Table 8. Global Metformin-Pioglitazone Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Metformin-Pioglitazone Market Share by Region (2025-2030)
Table 10. Metformin-Pioglitazone Market Trends
Table 11. Metformin-Pioglitazone Market Drivers
Table 12. Metformin-Pioglitazone Market Challenges
Table 13. Metformin-Pioglitazone Market Restraints
Table 14. Global Metformin-Pioglitazone Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Metformin-Pioglitazone Market Share by Players (2019-2024)
Table 16. Global Top Metformin-Pioglitazone Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metformin-Pioglitazone as of 2023)
Table 17. Ranking of Global Top Metformin-Pioglitazone Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Metformin-Pioglitazone Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Metformin-Pioglitazone Product Solution and Service
Table 21. Date of Enter into Metformin-Pioglitazone Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Metformin-Pioglitazone Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Metformin-Pioglitazone Revenue Market Share by Type (2019-2024)
Table 25. Global Metformin-Pioglitazone Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Metformin-Pioglitazone Revenue Market Share by Type (2025-2030)
Table 27. Global Metformin-Pioglitazone Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Metformin-Pioglitazone Revenue Market Share by Application (2019-2024)
Table 29. Global Metformin-Pioglitazone Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Metformin-Pioglitazone Revenue Market Share by Application (2025-2030)
Table 31. North America Metformin-Pioglitazone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Metformin-Pioglitazone Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Metformin-Pioglitazone Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Metformin-Pioglitazone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Metformin-Pioglitazone Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Metformin-Pioglitazone Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Metformin-Pioglitazone Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Metformin-Pioglitazone Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Metformin-Pioglitazone Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Metformin-Pioglitazone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Metformin-Pioglitazone Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Metformin-Pioglitazone Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Metformin-Pioglitazone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Metformin-Pioglitazone Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Metformin-Pioglitazone Market Size by Country (2025-2030) & (US$ Million)
Table 46. Takeda Pharmaceuticals Company Detail
Table 47. Takeda Pharmaceuticals Business Overview
Table 48. Takeda Pharmaceuticals Metformin-Pioglitazone Product
Table 49. Takeda Pharmaceuticals Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 50. Takeda Pharmaceuticals Recent Development
Table 51. Mylan Company Detail
Table 52. Mylan Business Overview
Table 53. Mylan Metformin-Pioglitazone Product
Table 54. Mylan Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 55. Mylan Recent Development
Table 56. Teva Company Detail
Table 57. Teva Business Overview
Table 58. Teva Metformin-Pioglitazone Product
Table 59. Teva Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 60. Teva Recent Development
Table 61. Sandoz Company Detail
Table 62. Sandoz Business Overview
Table 63. Sandoz Metformin-Pioglitazone Product
Table 64. Sandoz Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 65. Sandoz Recent Development
Table 66. Aurobindo Pharma Company Detail
Table 67. Aurobindo Pharma Business Overview
Table 68. Aurobindo Pharma Metformin-Pioglitazone Product
Table 69. Aurobindo Pharma Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 70. Aurobindo Pharma Recent Development
Table 71. MACLEODS Company Detail
Table 72. MACLEODS Business Overview
Table 73. MACLEODS Metformin-Pioglitazone Product
Table 74. MACLEODS Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 75. MACLEODS Recent Development
Table 76. Torrent Pharmaceuticals Company Detail
Table 77. Torrent Pharmaceuticals Business Overview
Table 78. Torrent Pharmaceuticals Metformin-Pioglitazone Product
Table 79. Torrent Pharmaceuticals Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 80. Torrent Pharmaceuticals Recent Development
Table 81. Wellona Pharma Company Detail
Table 82. Wellona Pharma Business Overview
Table 83. Wellona Pharma Metformin-Pioglitazone Product
Table 84. Wellona Pharma Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 85. Wellona Pharma Recent Development
Table 86. BLUE CROSS Company Detail
Table 87. BLUE CROSS Business Overview
Table 88. BLUE CROSS Metformin-Pioglitazone Product
Table 89. BLUE CROSS Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 90. BLUE CROSS Recent Development
Table 91. Neurocon Inc Company Detail
Table 92. Neurocon Inc Business Overview
Table 93. Neurocon Inc Metformin-Pioglitazone Product
Table 94. Neurocon Inc Revenue in Metformin-Pioglitazone Business (2019-2024) & (US$ Million)
Table 95. Neurocon Inc Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metformin-Pioglitazone Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Metformin-Pioglitazone Market Share by Type: 2023 VS 2030
Figure 3. Tablets: 15 mg pioglitazone/1000 mg metformin HCl Features
Figure 4. Tablets: 30 mg pioglitazone/1000 mg metformin HCl Features
Figure 5. Global Metformin-Pioglitazone Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Metformin-Pioglitazone Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Drug store Case Studies
Figure 9. Metformin-Pioglitazone Report Years Considered
Figure 10. Global Metformin-Pioglitazone Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Metformin-Pioglitazone Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Metformin-Pioglitazone Market Share by Region: 2023 VS 2030
Figure 13. Global Metformin-Pioglitazone Market Share by Players in 2023
Figure 14. Global Top Metformin-Pioglitazone Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metformin-Pioglitazone as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Metformin-Pioglitazone Revenue in 2023
Figure 16. North America Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Metformin-Pioglitazone Market Share by Country (2019-2030)
Figure 18. United States Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Metformin-Pioglitazone Market Share by Country (2019-2030)
Figure 22. Germany Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Metformin-Pioglitazone Market Share by Region (2019-2030)
Figure 30. China Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Metformin-Pioglitazone Market Share by Country (2019-2030)
Figure 38. Mexico Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Metformin-Pioglitazone Market Share by Country (2019-2030)
Figure 42. Turkey Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Metformin-Pioglitazone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Takeda Pharmaceuticals Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 45. Mylan Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 46. Teva Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 47. Sandoz Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 48. Aurobindo Pharma Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 49. MACLEODS Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 50. Torrent Pharmaceuticals Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 51. Wellona Pharma Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 52. BLUE CROSS Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 53. Neurocon Inc Revenue Growth Rate in Metformin-Pioglitazone Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
